CD105 is a prognostic marker and valid endothelial target for microbubble platforms in cholangiocarcinoma

• DOI: 10.1007/s13402-020-00530-8
• Publication Date: 2020-05-28T10:02:57Z
• Authors: Amit Nair; Nicola Ingram; Eldo T. Verghese; Imeshi Wijetunga; Alexander F. Markham; Judy Wyatt; K. Rajendra Prasad; P. Louise Coletta
• Keywords: Adult; Male; Cholangiocarcinoma; Mice; 03 medical and health sciences; 0302 clinical medicine; Cell Line, Tumor; Biomarkers, Tumor; Animals; Humans; Aged; Aged, 80 and over; Original Paper; Microbubbles; Endoglin; Endothelial Cells; Middle Aged; Capillaries; 3. Good health; Platelet Endothelial Cell Adhesion Molecule-1; Bile Duct Neoplasms; Microvessels; Multivariate Analysis; Female

Abstract Purpose The current treatment outcomes in cholangiocarcinoma are poor with cure afforded only by surgical extirpation. efficacy of targeting the tumoural endothelial marker CD105 cholangiocarcinoma, as a basis for potential microbubble-based treatment, is unknown and was explored here. Methods Tissue expression quantified using immunohistochemistry 54 perihilar samples from patients who underwent resection single centre over ten-year period, analysed against clinicopathological data. In vitro flow assays microbubbles functionalised antibody were conducted to ascertain specificity binding murine SVR cells. Finally, CD105-microbubbles intravenously administered 10 Balb/c nude mice bearing heterotopic subcutaneous human extrahepatic (TFK-1 EGI-1) xenografts after which vivo assessed following contrast-enhanced destruction replenishment ultrasound application. Results Though not significantly associated any examined variable, we found that higher independently poorer patient survival (median 12 vs 31 months; p = 0.002). studies revealed significant cells comparison isotype control ( 0.01), well TFK-1 0.02) EGI-1 0.04) mouse xenograft vasculature. Conclusion Our results indicate biomarker eminently suitable microbubbles.